Net Income

As its Reliquias mine restart nears, Silver Mountain launches a major drill campaign at Caudalosa, aiming to capitalize on a bullish silver market.

SaaS growth expert Eric Shoemaker takes the helm at Keebo, aiming to scale its AI-powered platform amid soaring enterprise demand for cloud cost control.

Amid rising costs, Chuck E. Cheese offers a $49.99 all-inclusive family deal, challenging competitors who average over $125 for a similar outing.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

Fidelis Insurance Group completes a $163M repurchase of all shares from founding investor CVC, a move set to boost shareholder value ahead of its rebrand.

Neogen divests its pioneering genomics business for $160M to slash debt, while Zoetis bolsters its dominance in the animal health diagnostics market.

Manhattan's top landlord promotes Harrison Sitomer from intern to President, signaling a focus on stability as it navigates a complex office market.

With a strong cash position and promising drug candidate, Apogee Therapeutics is advancing multiple trials to challenge the I&I market with a new therapy.

Riding high on U.S. success, GEEK BAR returns to Europe with a reusable vape, a strategic pivot as the continent wages war on disposable products.

Hain Celestial completes sale of Terra and Garden of Eatin' to pay down debt, betting its future on the high-margin tea, yogurt, and baby food markets.

The New York-based bank will now originate FHA-insured loans nationwide, positioning it to capitalize on the growing demand for senior care facilities.

McFarlane Lake Mining's latest drill results reveal a massive 95.4-meter gold intersection, signaling a major expansion of its Juby gold project.

Lynk Pharmaceuticals reports its oral drug zemprocitinib met all goals in a late-stage study for atopic dermatitis, offering rapid itch relief and a strong safety profile.

A key clinical milestone for its MS drug azer-cel nets Precision BioSciences $7.5M, extending its financial runway and boosting hope for patients.

With a strong cash runway and pivotal trials underway, Sionna Therapeutics aims to revolutionize CF treatment with a novel class of NBD1 stabilizer drugs.

As childhood nearsightedness soars, a new contact lens offers hope by not just correcting vision but actively slowing its progression in key global markets.

With strong leasing, strategic sales, and new developments, BXP is proving that a 'flight to quality' can defy the broader office market downturn.

As AI-driven fraud skyrockets, the Canadian Bankers Association is arming citizens with new resources to spot scams and protect their finances.

Riding record gold prices, TRX Gold shatters production records and cleans its balance sheet, fast-tracking a major expansion at its Buckreef project.

Zymeworks lands $250M from Royalty Pharma in a non-dilutive deal, validating its cancer drug Ziihera and highlighting a new era of biotech financing.